GlobeNewswire: MacroGenics, Inc. Contains the last 10 of 304 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T11:24:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/07/2842713/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-2023-Financial-Results.html?f=22&fvtc=4&fvtv=26695MacroGenics Provides Update on Corporate Progress and 2023 Financial Results2024-03-07T21:01:00Z<![CDATA[ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/03/01/2839116/0/en/MacroGenics-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=26695MacroGenics to Participate in Upcoming Investor Conferences2024-03-01T22:48:27Z<![CDATA[ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2024:]]>https://www.globenewswire.com/news-release/2024/02/27/2836527/0/en/MacroGenics-Announces-Date-of-Fourth-Quarter-2023-Financial-Results-Conference-Call.html?f=22&fvtc=4&fvtv=26695MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call2024-02-27T22:45:00Z<![CDATA[ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 7, 2024, at 4:30 pm ET.]]>https://www.globenewswire.com/news-release/2024/02/02/2823069/0/en/MacroGenics-to-Participate-in-Upcoming-Investor-Conference.html?f=22&fvtc=4&fvtv=26695MacroGenics to Participate in Upcoming Investor Conference2024-02-02T21:30:00Z<![CDATA[ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference:]]>https://www.globenewswire.com/news-release/2024/01/08/2805874/0/en/MacroGenics-to-Participate-in-Upcoming-Investor-Conference.html?f=22&fvtc=4&fvtv=26695MacroGenics to Participate in Upcoming Investor Conference2024-01-08T21:30:00Z<![CDATA[ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference:]]>https://www.globenewswire.com/news-release/2023/11/06/2774465/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=26695MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results2023-11-06T21:01:00Z<![CDATA[ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023.]]>https://www.globenewswire.com/news-release/2023/11/02/2772875/0/en/MacroGenics-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=26695MacroGenics to Participate in Upcoming Investor Conferences2023-11-02T20:30:00Z<![CDATA[ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2023/10/31/2770665/0/en/MacroGenics-Announces-Date-of-Third-Quarter-2023-Financial-Results-Conference-Call.html?f=22&fvtc=4&fvtv=26695MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call2023-10-31T20:30:00Z<![CDATA[ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, November 6, 2023, at 4:30 pm ET.]]>https://www.globenewswire.com/news-release/2023/09/05/2737169/0/en/MacroGenics-Announces-Achievement-of-15-Million-Milestone-Related-to-Gilead-s-Nomination-of-a-Bispecific-Research-Program.html?f=22&fvtc=4&fvtv=26695MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program 2023-09-05T11:00:00Z<![CDATA[ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc. (NASDAQ: GILD), nominated the first of two research programs, leveraging MacroGenics’ DART® and TRIDENT® platforms for generating bispecific antibodies. This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.]]>https://www.globenewswire.com/news-release/2023/08/31/2735713/0/en/MacroGenics-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=26695MacroGenics to Participate in Upcoming Investor Conferences2023-08-31T20:30:00Z<![CDATA[ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:]]>